Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | FABP6 | P51161 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17650912 | 1.00 | OPRM1 (0.55) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| Pyridine SCHEMBL27519316 | 0.92 | OPRM1 (0.48) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL20818791 | 0.88 | OPRM1 (0.57) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL20818793 | 0.88 | OPRM1 (0.57) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL20819030 | 0.88 | OPRM1 (0.57) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL9044015 | 0.84 | OPRM1 (0.53) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL28449490 | 0.82 | OPRM1 (0.51) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL20818773 | 0.81 | OPRM1 (0.50) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL20818946 | 0.81 | OPRM1 (0.50) | OPRM1OPRL1GRIN2BMEN1KMT2A | |
| SCHEMBL20818770 | 0.81 | OPRM1 (0.50) | OPRM1OPRL1GRIN2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-113248506-A | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3822274-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-05-06 | — | — | US | disclosed |
| CN-107001372-B | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2021-04-27 | — | — | CN | disclosed |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3204386-B1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200237768-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-10398700-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190091230-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2019-03-28 | — | — | US | disclosed |
| US-10149849-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170296546-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-10-19 | — | — | US | disclosed |
| US-9737541-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| EP-3204386-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170042902-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9512124-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| WO-2016057370-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096841-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042902-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-20190091230-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-20160096841-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-20200237768-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-10149849-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-20170296546-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
| US-10398700-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | OPRM1 3471/4885OPRL1 4249/4885GRIN2B 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.